Skip to main content
. 2021 Oct 21;36(3):781–789. doi: 10.1038/s41375-021-01444-6

Fig. 4. TP53 status differentiates patients in the clinically defined high-risk group in paediatric B-NHL.

Fig. 4

Kaplan–Meier plots showing (A) progression-free and (B) overall survival for high, intermediate and low clinical risk groups, and (C) progression-free and (D) overall survival in high-risk patients according to the presence of any TP53 abnormality.